Johnson & Johnson

Johnson & Johnson’s share price falls after a $1.5 billion talc verdict—what this means for investors, regulators, and patient safety.

Johnson & Johnson faces a $1.5 billion talc verdict that could reshape its finances, reputation and product strategy.

Explore how Johnson & Johnson’s mounting talc litigation and regulatory risks could slash earnings, drive strategic pivots, and reshape its consumer health future.

J&J’s $1.3 billion talc verdict threatens brand equity and revenue, but diversified oncology growth and proactive safety plans aim to shield profits and restore trust.

Johnson & Johnson faces a talc lawsuit fallout while riding FDA‑approved Trufill gains, with oncology pipelines and patent strategies poised to offset risks.

Johnson & Johnson’s latest FDA approvals for TRUFILL n‑BCA and RYBREVANT FASPRO expand neurosurgical and NSCLC treatment options, while talc litigation highlights ongoing legal risks.

Johnson & Johnson’s Q4 investor call reveals new drug approvals, regulatory breakthroughs, and legal updates, offering investors deeper insight into its oncology strategy and financial outlook.

Johnson & Johnson faces Irish profit decline, $40 million talc verdict, yet gains new FDA‑approved prostate cancer drug AKEEGA, balancing risk and growth.

Johnson & Johnson faces a talc lawsuit verdict while winning FDA approval for a dual‑action prostate cancer drug, highlighting its risk‑management and innovation balance.

Johnson & Johnson faces a $40 M talc verdict while clinching FDA approval for AKEEGA, its precision‑medicine prostate cancer drug—highlighting legal risks and high‑growth opportunities.